Matrix Asset Advisors Inc. NY Has $11.54 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Matrix Asset Advisors Inc. NY decreased its position in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 2.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,788 shares of the medical instruments supplier’s stock after selling 1,078 shares during the quarter. Becton, Dickinson and accounts for approximately 1.8% of Matrix Asset Advisors Inc. NY’s investment portfolio, making the stock its 25th largest position. Matrix Asset Advisors Inc. NY’s holdings in Becton, Dickinson and were worth $11,535,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Icapital Wealth LLC bought a new position in shares of Becton, Dickinson and in the 1st quarter worth $31,000. Disciplined Investments LLC purchased a new position in Becton, Dickinson and during the 1st quarter valued at about $32,000. Rosenberg Matthew Hamilton grew its holdings in Becton, Dickinson and by 61.5% during the 1st quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 48 shares in the last quarter. Core Alternative Capital boosted its position in shares of Becton, Dickinson and by 688.2% during the 1st quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 117 shares during the last quarter. Finally, EverSource Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and during the 4th quarter valued at about $38,000. Institutional investors own 86.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BDX shares. The Goldman Sachs Group boosted their price objective on Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a research report on Tuesday, August 16th. Morgan Stanley decreased their target price on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a research note on Friday, July 15th. Stifel Nicolaus cut their price objective on shares of Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. Citigroup cut shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and reduced their price objective for the stock from $265.00 to $235.00 in a research note on Monday, July 11th. Finally, StockNews.com upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Saturday, September 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $277.63.

Becton, Dickinson and Trading Down 1.8 %

Shares of Becton, Dickinson and stock traded down $4.23 during trading hours on Friday, hitting $232.96. The company’s stock had a trading volume of 25,667 shares, compared to its average volume of 968,418. Becton, Dickinson and Company has a twelve month low of $231.46 and a twelve month high of $280.62. The firm has a fifty day moving average of $252.37 and a 200-day moving average of $253.93. The stock has a market cap of $66.44 billion, a price-to-earnings ratio of 40.89, a P/E/G ratio of 3.12 and a beta of 0.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.90 and a current ratio of 1.35.

Becton, Dickinson and (NYSE:BDXGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The company had revenue of $4.64 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter in the prior year, the business earned $2.74 EPS. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. Research analysts forecast that Becton, Dickinson and Company will post 11.31 EPS for the current year.

Becton, Dickinson and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Shareholders of record on Friday, September 9th will be given a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.49%. The ex-dividend date of this dividend is Thursday, September 8th. Becton, Dickinson and’s payout ratio is 60.00%.

Insider Activity

In related news, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction on Monday, August 15th. The stock was sold at an average price of $265.00, for a total value of $125,875.00. Following the transaction, the executive vice president now owns 3,331 shares in the company, valued at $882,715. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the completion of the transaction, the chief executive officer now directly owns 28,878 shares in the company, valued at $7,656,424.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP David Hickey sold 475 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $265.00, for a total value of $125,875.00. Following the transaction, the executive vice president now owns 3,331 shares of the company’s stock, valued at $882,715. The disclosure for this sale can be found here. Insiders sold a total of 19,160 shares of company stock valued at $5,036,751 over the last quarter. Company insiders own 0.50% of the company’s stock.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.